



Corrigendum: Overall Survival Prediction of Advanced Cancer Patients by Selection of the Most Significant Baseline Serum Biomarker Combination

OPEN ACCESS

Edited and reviewed by:

József Tímár,
Semmelweis University, Hungary

*Correspondence:

Daniel Deme
danieldeme_md@ymail.com

Received: 13 April 2022

Accepted: 27 April 2022

Published: 18 May 2022

Citation:

Deme D, Kovacs S and Telekes A (2022) Corrigendum: Overall Survival Prediction of Advanced Cancer Patients by Selection of the Most Significant Baseline Serum Biomarker Combination. *Pathol. Oncol. Res.* 28:1610517. doi: 10.3389/pore.2022.1610517

Daniel Deme^{1*}, Sandor Kovacs² and Andras Telekes¹

¹Department of Medical Oncology, Szent Lázár County Hospital, Salgótarján, Hungary, ²Department of Economical and Financial Mathematics, University of Debrecen, Debrecen, Hungary

Keywords: overall survival, advanced cancer, serum biomarkers, prognostic importance, CRP, albumin, PLR

A Corrigendum on

Overall Survival Prediction of Advanced Cancer Patients by Selection of the Most Significant Baseline Serum Biomarker Combination by Deme D, Kovacs S and Telekes A (2022). *Pathol. Oncol. Res.* 28:1610004. doi: 10.3389/pore.2022.1610004

In the original article, there was a mistake in **Table 2**. In the last column of PLR the wrong patient number is 57. The correct patient number is 47. The corrected **Table 2** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

TABLE 2 | Comparison of the median OS based on the cut-off value for each significant biomarker.

Cut-off value	CRP (mg/L)		Albumin (g/L)		PLR	
	>30.65	≤30.65	≤44.35	>44.35	>168.20	≤168.20
n=	16	59	47	28	28	47
Median OS (months)	4.89	17.71	8.94	21.54	6.67	18.20
Mann-Whitney test (Z statistic)	3.75		3.32		3.38	
p-value	<0.001		<0.001		<0.001	

Copyright © 2022 Deme, Kovacs and Telekes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original

author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.